当前位置: X-MOL 学术Cardiovasc. Res. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Role of PDE10A in vascular smooth muscle cell hyperplasia and pathological vascular remodelling
Cardiovascular Research ( IF 10.8 ) Pub Date : 2021-09-17 , DOI: 10.1093/cvr/cvab304
Lingfeng Luo 1, 2 , Yujun Cai 2 , Yishuai Zhang 2 , Chia G Hsu 2 , Vyacheslav A Korshunov 2 , Xiaochun Long 3 , Peter A Knight 4 , Bradford C Berk 2 , Chen Yan 2
Affiliation  

Aims Intimal hyperplasia is a common feature of vascular remodelling disorders. Accumulation of synthetic smooth muscle cell (SMC)-like cells is the main underlying cause. Current therapeutic approaches including drug-eluting stents are not perfect due to the toxicity on endothelial cells and novel therapeutic strategies are needed. Our preliminary screening for dysregulated cyclic nucleotide phosphodiesterases (PDEs) in growing SMCs revealed the alteration of PDE10A expression. Herein, we investigated the function of PDE10A in SMC proliferation and intimal hyperplasia both in vitro and in vivo. Methods and results RT-qPCR, immunoblot, and in situ proximity ligation assay were performed to determine PDE10A expression in synthetic SMCs and injured vessels. We found that PDE10A mRNA and/or protein levels are up-regulated in cultured SMCs upon growth stimulation, as well as in intimal cells in injured mouse femoral arteries. To determine the cellular functions of PDE10A, we focused on its role in SMC proliferation. The anti-mitogenic effects of PDE10A on SMCs were evaluated via cell counting, BrdU incorporation, and flow cytometry. We found that PDE10A deficiency or inhibition arrested the SMC cell cycle at G1-phase with a reduction of cyclin D1. The anti-mitotic effect of PDE10A inhibition was dependent on cGMP-dependent protein kinase Iα (PKGIα), involving C-natriuretic peptide (CNP) and particulate guanylate cyclase natriuretic peptide receptor 2 (NPR2). In addition, the effects of genetic depletion and pharmacological inhibition of PDE10A on neointimal formation were examined in a mouse model of femoral artery wire injury. Both PDE10A knockout and inhibition decreased injury-induced intimal thickening in femoral arteries by at least 50%. Moreover, PDE10A inhibition decreased ex vivo remodelling of cultured human saphenous vein segments. Conclusions Our findings indicate that PDE10A contributes to SMC proliferation and intimal hyperplasia at least partially via antagonizing CNP/NPR2/cGMP/PKG1α signalling and suggest that PDE10A may be a novel drug target for treating vascular occlusive disease.

中文翻译:

PDE10A在血管平滑肌细胞增生和病理性血管重塑中的作用

目的 内膜增生是血管重塑障碍的共同特征。合成平滑肌细胞 (SMC) 样细胞的积累是主要的根本原因。由于对内皮细胞的毒性,目前包括药物洗脱支架在内的治疗方法并不完美,因此需要新的治疗策略。我们对生长的 SMC 中环核苷酸磷酸二酯酶 (PDE) 失调的初步筛选揭示了 PDE10A 表达的改变。在此,我们研究了 PDE10A 在体外和体内的 SMC 增殖和内膜增生中的功能。方法和结果 进行 RT-qPCR、免疫印迹和原位邻近连接测定以确定合成 SMC 和受损血管中的 PDE10A 表达。我们发现 PDE10A mRNA 和/或蛋白质水平在生长刺激后在培养的 SMC 中以及在受伤的小鼠股动脉的内膜细胞中上调。为了确定 PDE10A 的细胞功能,我们重点关注其在 SMC 增殖中的作用。通过细胞计数、BrdU 掺入和流式细胞术评估 PDE10A 对 SMC 的抗有丝分裂作用。我们发现 PDE10A 缺乏或抑制使 SMC 细胞周期停滞在 G1 期,同时细胞周期蛋白 D1 减少。PDE10A 抑制的抗有丝分裂作用依赖于 cGMP 依赖性蛋白激酶 Iα (PKGIα),涉及 C-利钠肽 (CNP) 和颗粒状鸟苷酸环化酶利钠肽受体 2 (NPR2)。此外,在股动脉钢丝损伤的小鼠模型中检查了 PDE10A 的遗传耗竭和药理学抑制对新内膜形成的影响。PDE10A 敲除和抑制均使股动脉中损伤诱导的内膜增厚减少至少 50%。此外,PDE10A 抑制减少了培养的人隐静脉段的离体重塑。结论 我们的研究结果表明,PDE10A 至少部分通过拮抗 CNP/NPR2/cGMP/PKG1α 信号通路促进 SMC 增殖和内膜增生,并表明 PDE10A 可能是治疗血管闭塞性疾病的新型药物靶点。PDE10A 抑制减少了培养的人隐静脉段的离体重塑。结论 我们的研究结果表明,PDE10A 至少部分通过拮抗 CNP/NPR2/cGMP/PKG1α 信号通路促进 SMC 增殖和内膜增生,并表明 PDE10A 可能是治疗血管闭塞性疾病的新型药物靶点。PDE10A 抑制减少了培养的人隐静脉段的离体重塑。结论 我们的研究结果表明,PDE10A 至少部分通过拮抗 CNP/NPR2/cGMP/PKG1α 信号通路促进 SMC 增殖和内膜增生,并表明 PDE10A 可能是治疗血管闭塞性疾病的新型药物靶点。
更新日期:2021-09-17
down
wechat
bug